Trials / Completed
CompletedNCT05234346
ALACOVID Study for Vaccinated Subjects
An Open-Label, Pilot Study to Evaluate the Safety, Tolerability, and Efficacy of 5-ALA-Phosphate + SFC as an Immune System Enhancer Along With Vaccination Against SARS-CoV-2 Virus Infection
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 200 (actual)
- Sponsor
- Vedic Lifesciences Pvt. Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
In this study, it is hypothesized that administration of 5-ALA-Phosphate + SFC in subjects vaccinated against Covid-19 could contribute in enhancing the targeted function of the immune system, which might lead to re-activation and/or increase of the vaccination response. Thus, in the present study, we will be evaluating the safety and efficacy of 5-ALA-Phosphate + SFC in subjects receiving the Covid-19 vaccine.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | 150 mg 5-ALAPhosphate + SFC | 2 capsules in the morning after breakfast (before 11 AM) and 1 capsule in the evening after a snack or after dinner (before 8 PM) orally with water for 21 days. |
| OTHER | Placebo | No Description for the intervention |
Timeline
- Start date
- 2022-03-15
- Primary completion
- 2022-06-18
- Completion
- 2022-06-18
- First posted
- 2022-02-10
- Last updated
- 2022-07-11
Locations
4 sites across 1 country: India
Source: ClinicalTrials.gov record NCT05234346. Inclusion in this directory is not an endorsement.